Kornimate/medical-research-clean huggingface dataset:
the effect of lh-priming during early follicular phase in ivf treatment.

Conditions: Infertility

Summary: to evaluate the effect of lh-activity supplementation during the early follicular phase in gnrha down-regulated women undergoing ivf in terms of s-estradiol levels on hcg day by comparing different combinations with hp-hmg and r-fsh.


Eligibility criteria:
inclusion criteria: * females between the ages of 18- 38 years (both included) at the time of randomisation * patients for whom treatment with gonadotrophins and gnrh agonist (long protocol) in ivf setting is considered appropriate according to the criteria of the participating centre * infertility for at least 1 year before randomisation (except for tubal infertility) * a maximum of two previous consecutive unsuccessful ivf cycles (i.e. not resulting in an ongoing pregnancy * 25- 34 days of menstruation cycle * body mass index (bmi) \< 29 kg/m2 exclusion criteria: * any clinically significant systemic disease (e.g., insulin dependent diabetes) * endocrine or metabolic abnormalities (pituitary, adrenal, thyroid, pancreas, liver, or kidney) which can compromise participation in the study * any concomitant medications that would interfere with evaluation of study medications. specifically, any non-study hormonal therapy (except for thyroid medication), prostaglandin inhibitors (nsaids, including aspirin) and psychotropic agents (phenothiazine's, major tranquillisers) at the time of study entry. note: these medications are disallowed for the study duration. * presence of clinically significant uterine fibroids * undiagnosed vaginal bleeding * tumours of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus * pregnancy, lactation or contraindication to pregnancy - must be confirmed by negative urinary pregnancy test at randomisation
feasibility of ultra-sound guided radiofrequency ablation in the management of head and neck neoplasia.

Conditions: Head and Neck Neoplasia

Summary: to study the feasibility of radiofrequency ablation (rfa) via ultrasound guidance in the management of head and neck neoplasia.

the study evaluates the feasibility of radio-frequency ablation in the management of head and neck neoplasia.

Eligibility criteria:
inclusion criteria: * patients with head and neck neoplasia. exclusion criteria: * when the patient does not meet the inclusion criteria. * when the patient has a contra-indication of surgery or anesthesia. * if the patient refuses involvement in the study.

Keywords: radio-frequency ablation; head and neck neoplasia.
clinical decision support for atrial fibrillation and flutter

Conditions: Atrial Fibrillation and Flutter

Summary: atrial fibrillation (af) is a major public health problem: it impairs quality of life and independently heightens the risks of ischemic stroke, heart failure and all-cause mortality. af is a common reason for presenting to emergency departments (ed) in kaiser permanente northern california (kpnc) and is associated with frequent hospitalization. additionally, inter-facility hospitalization rates for af vary across kpnc. improvements in modifiable components of ed af care could potentially reduce low-yield hospitalizations and the associated costs, patient inconveniences, and complications that can ensue. real-time clinical decision support systems (cdss) can transform entrenched physician practices and improve patient outcomes. the investigators will conduct a stepped-wedge cluster randomized trial of a cdss intervention across 13 kpnc eds for the comprehensive management of acute af with the following three aims: 1) to evaluate the impact of the cdss intervention on index hospitalization rates; 2) to evaluate the impact of the cdss intervention on ed af rate and rhythm control process-of-care metrics; and 3) to evaluate the impact of the cdss intervention on af stroke prevention actions for eligible participants at the time of ed discharge. the investigators hypothesize that the cdss intervention will safely reduce index hospitalization rates, improve rate and rhythm control process-of-care metrics, and increase stroke prevention actions for eligible participants at ed discharge and within 30 days.


Eligibility criteria:
inclusion criteria: * adult (≥18y) kpnc members presenting to the ed with a primary ed diagnosis of atrial fibrillation/flutter (af/fl). subjects who meet criteria will be identified electronically within the cdss tool in the electronic health record. exclusion criteria: * children (\<18y). * non-members of kpnc. * patients who were prisoners, pregnant, receiving hospice or palliative care, or who left against medical advice at the index encounter for af/fl.
alternate-day buprenorphine administration. phase vi - 7

Conditions: Opioid-Related Disorders

Summary: the purpose of this study is to determine if four times a subject's daily maintenance dose will hold for 96 hours without changes in agonist and antagonist effects.


Eligibility criteria:
please contact site for information.
building a traditional chinese medicine clinical diagnosis and treatment database

Conditions: Medicine, Chinese Traditional; Artificial Intelligence

Summary: collecting traditional chinese medicine (tcm) clinical diagnosis and treatment data, including doctor-patient dialogues, tongue diagnosis, facial diagnosis, and tcm constitution information, to construct databases for tongue diagnosis, tcm constitution, and doctor-patient dialogues. based on artificial intelligence technology, engage in research related to the standardization and intelligentization of tcm.

the technological principles of large language models align with the empirical medical principles of traditional chinese medicine (tcm), and the rise of large model technology can greatly promote the progress of tcm. however, there is currently a lack of clinical diagnosis and treatment databases with tcm characteristics for training tcm artificial intelligence(ai) large models. at present, a large-scale tongue image database has not yet been established for modeling common tcm tongue appearances, thereby ensuring the accuracy and consistency of tcm diagnosis and promoting the objective standardization of tcm diagnostic development. considering the feedback from the subjects in clinical work that the tcm constitution survey questionnaire has a large volume, takes a long time, and has certain subjective issues, we plan to carry out a large-scale clinical observational study to optimize the process of tcm constitution identification. traditional chinese medicine (tcm) doctor-patient dialogues and medical record writing are essential entities generated during the tcm diagnosis and treatment process. assisting in consultation, medical record generation, and treatment plan recommendations based on doctor-patient dialogues have significant clinical and research value. therefore, we plan to collect a large number of doctor-patient dialogues and outpatient medical records to construct a doctor-patient dialogue database, preparing in advance for optimizing interactive large-scale tcm models. in summary, the research on constructing a tcm clinical diagnosis and treatment database has important clinical and scientific research value. this will help to improve the standardization and normalization of tcm diagnosis and treatment, and also support the modernization and internationalization of tcm. by applying big data analysis and artificial intelligence technology, it is possible to delve deeper into tcm diagnosis and treatment information, providing richer and more accurate data resources for clinical decision-making and scientific research exploration in tcm.

Eligibility criteria:
inclusion criteria: * people who come to the hospital for physical examination and medical treatment； * participants voluntarily participate in the study. exclusion criteria: * subjects with difficulty in tongue extension, communication, etc. who cannot cooperate with data collection； * the researchers determined that there were other factors that may have forced the subjects to terminate the study.
a study of efficacy and safety of eltoprazine hcl for treating levodopa-induced dyskinesia in parkinson's disease patients

Conditions: Parkinson's Disease; Dyskinesia

Summary: the purpose of this study is to evaluate the safety, tolerability and efficacy of eltoprazine to treat levodopa-induced dyskinesia in patients with parkinson's disease

a double-blind, placebo-controlled, crossover, dose-range finding study in patients with parkinson's disease and levodopa-induced dyskinesia. the study will examine the effects of three different doses of eltoprazine hcl, compared to placebo, on severity of dyskinesia, parkinsonian symptoms, patient function, safety and tolerability, using parkinson's disease rating scales, patient diaries and physiological measurement of abnormal movement by means of motion sensors.

Eligibility criteria:
inclusion criteria: * outpatient with idiopathic pd * stable dose of anti-parkinsonian medication for at least four weeks before the screening visit * daily levodopa dose ≥300 mg per day divided into at least three doses * treated with levodopa for at least three years prior to study entry * moderate to severely disabling levodopa-induced dyskinesia for at least three months prior to study entry * dyskinesia for, on average, \>25% of the waking day exclusion criteria: * inability to use the motion sensors or electronic diaries correctly * surgical treatment for pd, e.g. deep brain stimulation, within the last six months or planned during the study * unstable co-existing psychiatric disease including psychosis, depression or cognitive impairment * mini mental state examination score of \<24 * moderate or severe renal, or severe hepatic, impairment * treatment with selective serotonin re-uptake inhibitors (ssri) or any combined serotonin-norepinephrine re-uptake inhibitors (snri), such as tryptizol, citalopram, escitalopram, sertraline, mianserin, mirtazapin, paroxetin, venlafaxine and st john's wort, within four weeks prior to the screening visit * treatment with medications with the potential for drug-interactions (mao-a inhibitors, apomorphine, aripiprazol, carbamazepine, clozapine, phenytoin, tramadol, quetiapine, varfaine, valproic acid). patients taking amantadine will comprise no more than 25% of the study population * current history of a clinically significant and uncontrolled medical condition that may affect the safety of the patient or preclude adequate participation in the study * pregnant or breast-feeding * received any other investigational medicinal product within 30 days of screening

Keywords: levodopa dyskinesia parkinsons disease pd
efficacy and safety of ckd-501 added to d150 plus d745 10mg therapy in patients with type 2 diabetes

Conditions: Type2 Diabetes

Summary: the purpose of this study is to prove that the group treated with ckd-501 in combination added that the reduction of glycated hemoglobin superior to placebo treated group added in combination.

the aim of this phase iii study was to evaluate the efficacy and safety of additional combined ckd-501 administration for 24 weeks in patients with type 2 diabetes who were not adequately controlled for blood glucose by the combination of d150 and d745 10mg . furthermore, the extension study for additional 28 weeks is designed to confirm long term safety of ckd-501 as an oral hypoglycemic agent.

Eligibility criteria:
inclusion criteria: * between 19 years and 75 years old(male or female) * type ⅱ diabetes mellitus * the patient who has been taking oral hypoglycemic agent at least 8weeks with hba1c 7 to 10% at screening test * bmi between 21kg/㎡ and 40kg/㎡ * c-peptide level is over 1.0 ng/ml * agreement with written informed consent * hba1c 7 to 10% after run-in period exclusion criteria: * type i diabetes or secondary diabetes * continuous or non continuous treatment(over 7 days) insulin within 3 months prior to screening * treatment with tzd within 3months or patient who have experience such as hypersensitivity reaction, serious adverse event or no effect by treatment with tzd, sglt2, bu * chronic(continuous over 7 days) oral or non oral corticosteroids treatment within 1 month prior to screening * treatment with anti-obesity drugs within 3months * past history: lactic acidosis or metformin contraindication * acute or chronic metabolic acidosis including diabetic ketoacidosis * history of proliferative diabetic retinopathy * severe infection, severe injury patients, patients of pre and post operation * patients with urinary tract infection including urinary tract sepsis and pyelonephritis * malnutrition, weakness, starvation, hyposthenia, pituitary insufficiency or adrenal insufficiency * history of malignant tumor within 5years * drug abuse or history of alcoholism * severe pulmonary dysfunction, severe gi disorder * history of myocardial infarction, heart failure, cerebral infarction, cerebral hemorrhage or unstable angina within 6 months * fasting plasma glucose level is over 270 mg/dl * triglyceride level is 500 mg/dl and over * significant abnormal liver dysfunction * anemia * abnormality of thyroid function(out of significant normal tsh range ) * egfr is less than 60ml/min/1.73m\^2 * pregnant women or nursing mothers * fertile women who not practice contraception with appropriate methods * participated in other trial within 4 weeks * participating in other trial at present * in investigator's judgment
eylea post marketing surveillance(pms)

Conditions: Macular Degeneration

Summary: the objective of this pms is to gain information about safety and efficacy in real practice as a regulatory commitment required by mfds


Eligibility criteria:
inclusion criteria: * patients determined to start eylea treatment * patients who agree and sign informed consent * patients who receive eylea treatment for the first time * patients who meet one of the following * patients diagnosed by physician as having neovascular (wet) age-related macular degeneration wamd * patients diagnosed by physician as having visual impairment due to macular edema secondary to retinal vein occlusion (branch rvo or central rvo) * patients diagnosed as having visual impairment due to diabetic macular edema (dme) * patients diagnosed as having visual impairment due to myopic choroidal neovascularization (mcnv) exclusion criteria: * patients who have received anti-vegf therapy within 90 days * patients who are contraindicated based on the approved product label * ocular or periocular infection * active severe intraocular inflammation * known hypersensitivity to any ingredient of this drug
comparison of the efficacy and satisfaction of blood glucose management between continuous glucose monitoring versus traditional self-blood glucose measurement in diabetic patients after pancreatectomy

Conditions: Diabetes Mellitus

Summary: this study aims to compare the efficacy and satisfaction of blood glucose management between continuous glucose monitoring versus traditional self blood glucose measurement in diabetic patients after pancreatectomy.

patients will be enrolled after the 75g oral glucose tolerance test performed 7 days after pancreatectomy. patients will be divided into two groups by randomization (continuous glucose measurement method vs. traditional self blood glucose measurement method), and 3months after surgery, hba1c, hypoglycemic events, and satisfaction would be compared.

Eligibility criteria:
inclusion criteria: * patients over 19 years of age * preoperative diabetes history * patients who underwent subtotal or total pancreatectomy * patients who were diagnosed with diabetes mellitus in the evaluation of endocrine function test on the 7th day after pancreaticoduodenectomy, central pancreatectomy, or distal pancreatectomy exclusion criteria: * patients who have used continuous blood glucose measurement device more than once before. * elderly patients who are not accustomed to using the smartphone applications * serious systemic diseases that can affect diabetes (chronic kidney disease, heart failure, decompensated liver cirrhosis, etc.) * steroid user during the study period * major medical or psychiatric condition that will affect response to treatment
real-time deflectable guidewire in neuro-interventions study

Conditions: Unruptured Cerebral Aneurysm

Summary: the aim of the study is to assess the safe and successful use of the smartguide guidewire in neuro interventions and to compare to standard of care guidewires on the market.


Eligibility criteria:
inclusion criteria: * \>18 years of age * informed consent signed by patient * confirmed cerebral unruptured aneurysm treatable via transcatheter approach exclusion criteria: * pregnancy or lactation * known disorder of vascular fragility with propensity to vascular injury (e.g., ehlers-danlos syndrome) * known prior vascular stenosis or dissection or injury to vessels intended to be catheterized during study procedures * acute phase myocardial infarction or uncontrolled cardiac arrhythmia * uncontrolled serum electrolyte imbalance * bleeding disorder which limits the use of antiplatelet and/or anticoagulant therapy * known contraindication to intravascular contrast material that cannot be adequately controlled with pre-medication * known hypersensitivity to nickel * subjects currently enrolled in another investigational device or drug study that clinically interferes with the current study endpoints
is respiratory muscle strength, peripheral muscle strength and postural control affected in scoliosis?

Conditions: Adolescent Idiopathic Scoliosis

Summary: the vertebral column is a structure that transfers the weight of the head and torso to the lower extremity, provides trunk movements and protects the spinal cord.a three dimensional deformity involving lateral flexion of the vertebrae in the frontal plane at 10 ° and above, including axial rotation and physiologic flexion (hypokyphosis) components in the sagittal plane, is defined as scoliosis. adolescent idiopathic scoliosis (ais) is a type of idiopathic scoliosis that occurs in the period from the onset of puberty (up to 10 years) until the closure of growth plates. scoliosis is caused by postural, balance and neuromotor disorders as a primary cause of impaired sensory integrity, proprioceptive feedback deficits, secondary lung problems, organ disorders and pain. children with adolescent idiopathic scoliosis have inadequate respiratory function. at the same time, these children show muscle weakness in certain parts of the body. the aim of this study is to compare young adolescents with scoliosis with their healthy peers and examine whether respiratory muscle strength, peripheral muscle strength and postural control are affected.


Eligibility criteria:
inclusion criteria: * individuals agreeing to participate in the study * in the age range of 10-20 * patients with scoliosis with a cobb angle of 15-40 degrees measured on x-ray exclusion criteria: * surgical operation in the last 3 months * having mental, communicative and behavioral disorders that may cause problems understanding commands and questions or performing exercises.

Keywords: scoliosis adolescent idiopathic scoliosis respiratory muscle strength peripheral muscle strength postural control
long-term control in rhinosinusitis after functional endoscopic sinus surgery (fess)

Conditions: Condition of Patient 3 Years After FESS-operation

Summary: state-of-the-art documents like aria and european position paper on rhinosinusitis (epos) provide clinicians with evidence-based treatment algorithms for allergic rhinitis (ar) and chronic rhinosinusitis (crs) respectively (1)(2) . the currently available medications can alleviate symptoms associated with ar and rs, and most patients with rs benefit from endoscopic sinus surgery (ess). in real life, a significant percentage of patients with ar and crs continue to experience bothersome symptoms despite adequate treatment. this group with so-called severe chronic upper airway disease (scuad) represents a therapeutic challenge (3).


Eligibility criteria:
inclusion criteria: 1. patients that have undergone bilateral ess for inflammatory sinonasal disease, without additional sino-nasal surgery after the ess. 2. age \> 18 and \< 75 years. 3. written informed consent 4. dutch, french or english speaking patients exclusion criteria: 1. unilateral ess 2. benign and malignant tumor disease 3. patient with a psychiatric, addictive, or any disorder of which the investigators feel at the time of evaluation for participation in the study that this may compromise the ability to give truly informed consent for participation in this study or provide reliable information on the questionnaire 4. lack of knowledge of dutch, french or english
optimizing surgical conditions during gynecologic laparoscopic surgery with deep neuromuscular blockade

Conditions: Neuromuscular Blockade

Summary: to investigate if deep neuromuscular blockade improves intraabdominal volume compared to no neuromuscular blockade in patients scheduled for gynecologic laparoscopic surgery with pneumoperitoneum 12 mmhg. hypothesis: deep neuromuscular blockade improves intraabdominal space (the distance from promontorium to skin surface, cm) compared to no neuromuscular blockade.


Eligibility criteria:
inclusion criteria: * patients \> 18 years old * elective laparoscopic operation * can read and understand danish * informed consent exclusion criteria: * bmi \> 30 kg/cm2 * known allergy to medications that are included in the project, * severe renal disease, defined by s-creatinine\> 0,200 mmol/l, gfr \< 30ml/min or hemodialysis), * neuromuscular disease that may interfere with neuromuscular data, * lactating or pregnant, * impaired liver function, * converting to laparotomy, * perioperative use of neuromuscular blocking agents before randomization, * pneumoperitoneum set to \>12 mmhg on the insufflator

Keywords: surgical conditions laparoscopy
feasibility study for the comprehensive overweight/obesity management pre-kidney transplant (compkt) program

Conditions: Kidney Transplant; Complications; Obesity

Summary: this project will be a single-arm feasibility study, with a treatment intervention that includes three interrelated components: (1) patient education using a proven weight loss curriculum, and (2) technology tools for making healthy lifestyle choices.

to optimize care for overweight/obese patients who are awaiting kidney transplants by implementing a referral process and a multi-pronged, team-based nurse/pharmacist/dietitian weight loss treatment intervention to help these patients achieve transplant criteria. obesity, hypertension, and esrd disproportionately affect the black community, and black patients have been historically disadvantaged by race-inclusive calculations that overestimated their kidney function. effective january 5, 2023, the organ procurement and transplantation network board of directors requires use of a race-neutral estimated glomerular filtration rate (egfr) to qualify candidates for kidney transplant. they also required transplant programs to identify black candidates who may have been wrongly denied qualification

Eligibility criteria:
inclusion criteria: * on the waiting list for kidney transplant at vcuhs * bmi greater than 35 kg/m2 exclusion criteria: * children, prisoners, pregnant women